OLFML3 and breast cancer: Another study on non-metastatic BC treated with neoadjuvants revealed that lower expression of CIQTNF3, CTF1, OLFML3, PLA2RI, PODN, KRTI5, and HLA-A and overexpression of TUBB and TCPI was characteristic for patients with chemoresistance and with poor prognosis.